If two New Hampshire men aren't a match for the Devil, we might as well give the country back to the Indians. -Stephen Vincent Benet (1898-1943)
For Many Americans, Covid Is Still a Chronic, Disabling Disease. These Scientists Are Working Tirelessly to Bring Them Relief (Mike Mariani, September/October 2026, Smithsonian)
The PLRC and other like-minded groups have outlined more than 200 associated symptoms, including fatigue, muscle weakness, joint pain, sore throat, insomnia, difficulty concentrating, memory issues and post-exertional malaise…
At least pretend it’s physical.
An Insider’s Look at What Happened When Chiropractic Was Evaluated Scientifically, and Why No One Remembers (J. Michael Menke, August 27, 2026, Skeptic)
During the 1980s and 1990s chiropractic researchers launched clinical trials, comparative-effectiveness studies, and collaborations with universities and medical centers.
Then, the larger, better-designed studies made the clinical picture go soft. Patients improved—sometimes substantially—but the improvement proved stubbornly hard to pin on manipulation. Natural history, spontaneous recovery, reassurance, exercise, attention, expectancy, and plain contextual healing kept blurring the causal thresholds.2 Manipulation generally performed about as well as any other conservative care including placebo, and when superior, it closely tracked the false positive rate expected under null hypothesis significance testing.3, 4 In fact, to this day you will see chiropractic research conclusions proudly assert that manipulation is no less effective than other treatments for low back pain, including controls—a damnation by faint self-praise.
The problem was not only scientific but psychological, cultural, and institutional, which is why supporters and critics could read the same trials as Rorschach blots and come away convinced of opposite conclusions. When one body of evidence underwrites both conclusions, the fault is rarely bias; more often the evidence was never built to answer the question asked of it.5 The remedy is unglamorous: decide in advance which single measure could settle the question, weigh several rival hypotheses at once,6 and recognize when further information can no longer move the decision.7 In short: name in advance the result that would change your mind. Chiropractic, though, thrived in the ambiguity. When outcomes were positive, manipulation worked; when they were negative, prejudice or incompetence was clearly afoot.
So the center of gravity in chiropractic research quietly retreated from the awkward clinical effectiveness question, towards safer, fundable territory: biomechanics, sensorimotor physiology, adverse-event surveillance, health-services research, and broad biopsychosocial models.
Does spinal manipulation itself produce large, reliable, clinically transformative effects beyond natural history and contextual healing?
I eventually tried to answer that question—at scale, assembling a meta-analysis of spinal manipulation for low back pain: a hundred and twenty randomized trials, some nineteen thousand patients, modeled against the natural history of recovery. The results did not rescue the story I had spent my youth defending. Once natural history and contextual healing were given their due, the slight effect we detected turned out to be natural history carrying manipulation for acute pain and a faint placebo carrying it for chronic pain.8, 9 Years later, a contemporary from those reform days, chiropractor, influencer, and fellow researcher Greg Plaugher, remarked to me that “evidence-based chiropractic” was an old and abandoned paradigm.10
Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster? (Dr. Tim Sandle, August 26, 2026, Digital Journal)
The traditional process of drug discovery is lengthy and complex. Scientists must identify disease-causing biological targets, design molecules capable of interacting with those targets, test thousands of candidates, and then determine whether any are safe and effective enough to progress into clinical development. It is an expensive undertaking that is frequently described as taking around a decade and billions of dollars to bring a successful medicine to market.
Artificial intelligence (AI) is increasingly being positioned as a solution to this challenge. Across academia and industry, researchers are combining AI algorithms with powerful computational infrastructure to identify promising drug candidates more rapidly.
The True Science and History Behind the Blue Fugates of Kentucky: The Blue Fugates of Kentucky (1820-1975) were an Appalachian family whose skin turned blue due to hereditary methemoglobinemia caused by an enzyme deficiency. (Madison Whipple, 8/20/26, The Collector)
In 1960, a young hematologist named Madison Cawein began hearing rumors at the University of Kentucky. People spoke about the blue hill folks of the Cumberland Plateau. There were blue Stacys, Combses, Smiths, and Fugates at that time as a result of inbreeding and the small gene pool from which many of Eastern Kentucky’s families came.
Cawein was an accomplished doctor. He helped isolate the antidote for cholera and helped create a drug for Parkinson’s Disease. He was, however, a hematologist at heart. Cawein said that “blood cells always looked beautiful to me,” so when he began hearing about the blue people, his interest was piqued.
Cawein, along with Ruth Pendergrass, a nurse from the American Heart Association clinic in Hazard, scoured the hollers for blue people. Pendergrass was fascinated with the blue people since she gave a blood test to a woman who identified herself as a blue Combs from Ball Creek. Cawein and Pendergrass went on daily missions to find blue people until they were frustrated and near giving up. After all, Cawein was forced to drive eight hours one way, from Lexington to Hazard, when he wanted to go on a search. Then a pair of siblings, Rachel and Patrick Ritchie, walked into the heart clinic in Hazard. They were blue, and Cawein had found his white (or blue) whale.
Why MAGA Is So Obsessed With Fauci: In the aftermath of pandemics, people either try to forget them or find others to blame for them. (Peter Wehner, 8/12/26, The Atlantic)
[T]he scientific evidence favors a natural origin. This includes epidemiological evidence showing that the first COVID-19 cases clustered around one corner of Wuhan’s Huanan Seafood Wholesale Market, where wild animals were being butchered. Environmental samples taken from that same area of the market contain, in the same swab, the SARS-CoV-2 sequence and DNA from potential intermediate hosts such as the raccoon dog.
The accusation that Fauci lied to Congress rests on his denial, in a 2021 exchange with Paul, that NIH had ever funded gain-of-function research at the Wuhan lab. The point of such research is to learn what a virus would need to jump into humans before it does, so that vaccines and treatments can be ready.
The trouble is the term gain of function. In biology, it means research that gives an organism a new capability—engineering a bacterium to digest an oil spill is gain-of-function research. In politics, it has come to mean something narrower and more alarming: deliberately making a dangerous virus more dangerous. Federal rules use a third definition, narrower still. The federal framework adopted in 2017, after years of public debate, covers work to enhance a pathogen that is “likely highly transmissible and likely capable of wide and uncontrollable spread in human populations” and “likely highly virulent and likely to cause significant morbidity and/or mortality in humans.” It also excludes viruses, however dangerous, as they exist in nature. (The policy was revised in 2024.)
The gap between those definitions is the whole dispute, and it is why the perjury charge fails twice over.
AI’s Coming Revolutionary Effect on Third World Healthcare (Andy Wong Ming Jun, 8/09/26, Asia Sentinel)
This illustrates the growing impact of artificial intelligence (AI) on healthcare delivery and service quality in lower-income regions, from Africa to Southeast Asia. Physicians with limited training or experience are increasingly using their phones to call up AI as a supplementary tool for diagnosis and prescription decisions.
Beyond that, AI is supporting faster screening, improving diagnostic accuracy, and reducing prescription errors. According to a recent study, AI-assisted tuberculosis screening reduced misdiagnosis rates by more than 30 percent and improved predictive forecasting of seasonal disease outbreaks by more than 80 percent.
Genetic tracing of market wildlife and viruses at the epicenter of the COVID-19 pandemic (Cell, 2024)
Zoonotic spillovers of viruses have occurred through the animal trade worldwide. The start of the COVID-19 pandemic was traced epidemiologically to the Huanan Seafood Wholesale Market. Here, we analyze environmental qPCR and sequencing data collected in the Huanan market in early 2020. We demonstrate that market-linked severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic diversity is consistent with market emergence and find increased SARS-CoV-2 positivity near and within a wildlife stall. We identify wildlife DNA in all SARS-CoV-2-positive samples from this stall, including species such as civets, bamboo rats, and raccoon dogs, previously identified as possible intermediate hosts. We also detect animal viruses that infect raccoon dogs, civets, and bamboo rats. Combining metagenomic and phylogenetic approaches, we recover genotypes of market animals and compare them with those from farms and other markets. This analysis provides the genetic basis for a shortlist of potential intermediate hosts of SARS-CoV-2 to prioritize for serological and viral sampling.
A new kind of drug points to where medicine is headed (Priscilla Duggan, July 30, 2026, Larchmont Chronicle)
Just this past May, the Food and Drug Administration approved a new drug named vepdegestrant (Veppanu) for a subset of patients suffering from metastatic breast cancer. First and foremost, this is a promising development for individuals with oestrogen receptor-positive, HER2-negative breast cancer. However, there is an extra layer of excitement to this news: Veppanu is the first drug of its kind (known as a PROTAC) to ever be approved by the FDA. For the remainder of the article, I will go over exactly what I mean by this and unpack all these science terms.Let’s break it down into simple concepts: proteins are everywhere in the body. Receptors, enzymes, structural elements—they’re all made up of proteins. Many diseases stem from proteins that aren’t behaving as expected. For example, an overactive protein could lead to cancer, or a misfolded protein could lead to a neurodegenerative disease. Therefore, many existing drugs work by blocking a protein’s function.
PROTACs (which is short for proteolysis-targeting chimera) work in a completely different way. In simple terms, they stick onto a specific protein and bring it to our cell’s natural garbage-disposal system.
What is this “garbage disposal system”? In biology, when a protein needs to be destroyed by the body, this is referred to as “ubiquitination.” A faulty or misfolded protein that needs to be destroyed is first “tagged” with a little flag called an E3 ligase. This flag calls over another protein called ubiquitin, the cell’s garbage man. Basically, ubiquitin’s job is to destroy whatever the E3 is connected to. […]
Medicine is learning not only how to inhibit problematic proteins, but how to remove them. Consider the plethora of diseases caused by protein malfunction: Alzheimer’s, Parkinson’s, Huntington’s, cystic fibrosis—the list goes on. With this in mind, this step forward has promising implications for many diseases that have long been considered non-treatable.
5 Sneaky Daytime Signs of Sleep Apnea, According to Doctors: If you’re experiencing any of the symptoms on this list, it’s time to see your healthcare provider. (Emily Laurence Sardinha, 7/29/26, Parade)
“The most common daytime symptom of sleep apnea is tiredness or fatigue,” reiterates Dr. Brooke Judd, MD, the Section Chief of Sleep Medicine at Dartmouth Health. “Sometimes this is severe sleepiness to the point that someone may unintentionally fall asleep during a conversation or while driving, but it doesn’t have to be that obvious.”
The path to artificial superintelligence (MIT Technology Review Insights, July 27, 2026)
Imagine a healthcare system made up of multiple AI agents: one that manages symptom assessment, another scheduling, a third insurance, and a fourth pharmacy.
Each is an expert in its domain. But they all have their own distinct knowledge and objectives. Today they can exchange data, but they are not yet able to actually coordinate patient care without a human making the decisions.
“The intelligence is already there. What is missing is the connective tissue that turns four strangers into one team,” explains Vijoy Pandey, senior vice president and general manager of Outshift by Cisco.
This “connective tissue” comes from adding a semantic layer—what Outshift calls the “Internet of Cognition”—that enables agents across domains to work together and, critically, “think” together through shared intent, context, and reasoning.